Topical ENS-002 for Atopic Dermatitis in Adults

This is a Phase 1, open-label, non-randomized, study investigating ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal non-pathogenic bacteria The purpose of this dose escalation study is to determine the recommended Phase 2 dose (RP2D) of ENS-002 in participants with mild, moderate or severe atopic dermatitis. Participation in this study will continue until dose limiting toxicity or therapy intolerance, or participant withdrawal.